作者
Fiona Heeman, Janine Hendriks, Catarina Tristão‐Pereira, Lyduine E Collij, Peter Young, Bart NM van Berckel, Pieter Jelle Visser, Bernard J Hanseeuw, Rik Vandenberghe, Valentina Garibotto, Giovanni B Frisoni, Daniele Altomare, Mahnaz Shekari, Christopher Buckley, Gill Farrar, Mark E Schmidt, Rossella Gismondi, Andrew W Stephens, Craig W Ritchie, Catriona Wimberley, Pablo Martinez‐Lage, Richard Manber, Robin Wolz, Juan Domingo Gispert, Michael Schöll, Isadora Lopes Alves, Frederik Barkhof, David Vállez García, Adriaan A Lammertsma, Maqsood Yaqub, AMYPAD consortium
发表日期
2023/12
期刊
Alzheimer's & Dementia
卷号
19
页码范围
e079545
简介
Background
Amyloid‐β (Aβ) PET is commonly used for studying the earliest phases of Alzheimer’s disease (AD) in cognitively unimpaired (CU) individuals. In this group, the expected changes in Aβ pathology are small, which emphasizes the importance of selecting a method with the highest possible precision for measuring these changes. This study compared several methods for quantifying Aβ pathology longitudinally in mostly CU individuals from the AMYPAD‐PNHS cohort.
Method
Participants were scanned with either [18F]flutemetamol (baseline N = 360, follow‐up N = 243) or [18F]florbetaben (N = 66 baseline, N = 49 follow‐up), according to a dual‐time window protocol(Table 1). A subset of participants had ≥2 timepoints available (N = 206, N = 43, respectively). SUVRs were calculated, and parametric modelling was performed using RPM, SRTM2, RLogan, MRTM0, MRTM and MRTM2 using PPET …
学术搜索中的文章
F Heeman, J Hendriks, C Tristão‐Pereira, LE Collij… - Alzheimer's & Dementia, 2023